25 XP   0   0   10

Kalbe Farma Tbk PT ADR
Buy, Hold or Sell?

Let's analyse Kalbe together

PenkeI guess you are interested in Kalbe Farma Tbk PT ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kalbe Farma Tbk PT ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kalbe Farma Tbk PT ADR

I send you an email if I find something interesting about Kalbe Farma Tbk PT ADR.

Quick analysis of Kalbe (30 sec.)










What can you expect buying and holding a share of Kalbe? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$6.12
Expected worth in 1 year
$5.07
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
$-1.05
Return On Investment
-5.0%

For what price can you sell your share?

Current Price per Share
$21.05
Expected price per share
$21.05 - $21.05
How sure are you?
50%

1. Valuation of Kalbe (5 min.)




Live pricePrice per Share (EOD)

$21.05

Intrinsic Value Per Share

$-0.01 - $0.01

Total Value Per Share

$6.11 - $6.13

2. Growth of Kalbe (5 min.)




Is Kalbe growing?

Current yearPrevious yearGrowGrow %
How rich?$1.4b$1.4b-$72.4m-5.1%

How much money is Kalbe making?

Current yearPrevious yearGrowGrow %
Making money$22.8k$22.2k601.122.6%
Net Profit Margin11.7%12.1%--

How much money comes from the company's main activities?

3. Financial Health of Kalbe (5 min.)




What can you expect buying and holding a share of Kalbe? (5 min.)

Welcome investor! Kalbe's management wants to use your money to grow the business. In return you get a share of Kalbe.

What can you expect buying and holding a share of Kalbe?

First you should know what it really means to hold a share of Kalbe. And how you can make/lose money.

Speculation

The Price per Share of Kalbe is $21.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kalbe.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kalbe, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.12. Based on the TTM, the Book Value Change Per Share is $-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $0.82 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kalbe.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.0%0.000.0%1.366.5%0.723.4%0.723.4%
Usd Book Value Change Per Share-0.26-1.2%-0.26-1.2%0.823.9%-58.06-275.8%0.612.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.150.7%
Usd Total Gains Per Share-0.26-1.2%-0.26-1.2%0.823.9%-58.06-275.8%0.773.6%
Usd Price Per Share25.63-25.63-22.05-18.42-20.87-
Price to Earnings Ratio260,986.06-260,986.06-16.23-53,011.43-27,001.82-
Price-to-Total Gains Ratio-97.65--97.65-26.93--17.52--7.79-
Price to Book Ratio4.19-4.19-3.45-2.45-1.23-
Price-to-Total Gains Ratio-97.65--97.65-26.93--17.52--7.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share21.05
Number of shares47
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.26-58.06
Usd Total Gains Per Share-0.26-58.06
Gains per Quarter (47 shares)-12.34-2,728.64
Gains per Year (47 shares)-49.35-10,914.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-49-590-10915-10925
20-99-1080-21829-21840
30-148-1570-32744-32755
40-197-2060-43659-43670
50-247-2550-54573-54585
60-296-3041-65488-65500
70-345-3531-76403-76415
80-395-4021-87317-87330
90-444-4511-98232-98245
100-494-5001-109146-109160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%7.03.00.070.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%7.03.00.070.0%

Fundamentals of Kalbe

About Kalbe Farma Tbk PT ADR

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals and Distribution; and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Fundamental data was last updated by Penke on 2024-04-03 04:17:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kalbe Farma Tbk PT ADR.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kalbe earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 11.7% means that $0.12 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 11.7%. The company is making a huge profit. +2
  • The TTM is 11.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.7%TTM11.7%0.0%
TTM11.7%YOY12.1%-0.4%
TTM11.7%5Y11.7%+0.0%
5Y11.7%10Y11.7%-0.1%
1.1.2. Return on Assets

Shows how efficient Kalbe is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • 0.0% Return on Assets means that Kalbe generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 0.0%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.0%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.0%TTM0.0%0.0%
TTM0.0%YOY0.0%+0.0%
TTM0.0%5Y0.0%+0.0%
5Y0.0%10Y0.0%0.0%
1.1.3. Return on Equity

Shows how efficient Kalbe is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • 0.0% Return on Equity means Kalbe generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 0.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.0%TTM0.0%0.0%
TTM0.0%YOY0.0%+0.0%
TTM0.0%5Y0.0%+0.0%
5Y0.0%10Y0.0%0.0%

1.2. Operating Efficiency of Kalbe Farma Tbk PT ADR.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kalbe is operating .

  • Measures how much profit Kalbe makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 14.5% means the company generated $0.14  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 14.5%. The company is operating less efficient.
  • The TTM is 14.5%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ14.5%TTM14.5%0.0%
TTM14.5%YOY15.2%-0.7%
TTM14.5%5Y14.9%-0.4%
5Y14.9%10Y15.3%-0.4%
1.2.2. Operating Ratio

Measures how efficient Kalbe is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.86 means that the operating costs are $0.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 0.855. The company is less efficient in keeping operating costs low.
  • The TTM is 0.855. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.855TTM0.8550.000
TTM0.855YOY0.848+0.007
TTM0.8555Y0.957-0.102
5Y0.95710Y1.162-0.205

1.3. Liquidity of Kalbe Farma Tbk PT ADR.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kalbe is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 3.77 means the company has $3.77 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 3.771. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.771. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.771TTM3.7710.000
TTM3.771YOY4.445-0.674
TTM3.7715Y4.269-0.498
5Y4.26910Y3.992+0.277
1.3.2. Quick Ratio

Measures if Kalbe is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 2.04 means the company can pay off $2.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 2.037. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.037. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.037TTM2.0370.000
TTM2.037YOY2.908-0.871
TTM2.0375Y2.431-0.394
5Y2.43110Y1.797+0.634

1.4. Solvency of Kalbe Farma Tbk PT ADR.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kalbe assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kalbe to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.19 means that Kalbe assets are financed with 18.9% credit (debt) and the remaining percentage (100% - 18.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 0.189. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.189. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.189TTM0.1890.000
TTM0.189YOY0.171+0.017
TTM0.1895Y0.177+0.012
5Y0.17710Y0.189-0.013
1.4.2. Debt to Equity Ratio

Measures if Kalbe is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 25.2% means that company has $0.25 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kalbe Farma Tbk PT ADR:

  • The MRQ is 0.252. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.252. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.252TTM0.2520.000
TTM0.252YOY0.225+0.028
TTM0.2525Y0.228+0.024
5Y0.22810Y0.248-0.019

2. Market Valuation of Kalbe Farma Tbk PT ADR

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kalbe generates.

  • Above 15 is considered overpriced but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A PE ratio of 260,986.06 means the investor is paying $260,986.06 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kalbe Farma Tbk PT ADR:

  • The EOD is 214,348.679. Based on the earnings, the company is expensive. -2
  • The MRQ is 260,986.064. Based on the earnings, the company is expensive. -2
  • The TTM is 260,986.064. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD214,348.679MRQ260,986.064-46,637.385
MRQ260,986.064TTM260,986.0640.000
TTM260,986.064YOY16.232+260,969.831
TTM260,986.0645Y53,011.432+207,974.632
5Y53,011.43210Y27,001.824+26,009.608
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kalbe Farma Tbk PT ADR:

  • The EOD is 1,747,656.731. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 2,127,906.984. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 2,127,906.984. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1,747,656.731MRQ2,127,906.984-380,250.253
MRQ2,127,906.984TTM2,127,906.9840.000
TTM2,127,906.984YOY394,605.641+1,733,301.344
TTM2,127,906.9845Y766,939.798+1,360,967.186
5Y766,939.79810Y384,980.961+381,958.837
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kalbe is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 4.19 means the investor is paying $4.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kalbe Farma Tbk PT ADR:

  • The EOD is 3.438. Based on the equity, the company is fair priced.
  • The MRQ is 4.186. Based on the equity, the company is fair priced.
  • The TTM is 4.186. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.438MRQ4.186-0.748
MRQ4.186TTM4.1860.000
TTM4.186YOY3.454+0.733
TTM4.1865Y2.447+1.739
5Y2.44710Y1.232+1.215
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Kalbe Farma Tbk PT ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.263-0.2630%0.819-132%-58.057+22015%0.612-143%
Book Value Per Share--6.1226.1220%6.385-4%69.898-91%18080.221-100%
Current Ratio--3.7713.7710%4.445-15%4.269-12%3.992-6%
Debt To Asset Ratio--0.1890.1890%0.171+10%0.177+7%0.1890%
Debt To Equity Ratio--0.2520.2520%0.225+12%0.228+10%0.248+2%
Dividend Per Share--0.0000.0000%0.000+21%0.001-91%0.154-100%
Eps--0.0000.0000%1.358-100%0.720-100%0.719-100%
Free Cash Flow Per Share--0.0000.0000%0.000-78%0.001-98%0.001-98%
Free Cash Flow To Equity Per Share--0.0000.0000%0.000-98%0.000-152%0.000-400%
Gross Profit Margin---15537.985-15537.9850%-15038.957-3%-12869.108-17%-6434.054-59%
Intrinsic Value_10Y_max--0.005--------
Intrinsic Value_10Y_min---0.012--------
Intrinsic Value_1Y_max--0.001--------
Intrinsic Value_1Y_min--0.000--------
Intrinsic Value_3Y_max--0.002--------
Intrinsic Value_3Y_min---0.002--------
Intrinsic Value_5Y_max--0.003--------
Intrinsic Value_5Y_min---0.004--------
Market Cap4868401900.000-22%5961017762.2605961017762.2600%5167742406.750+15%201513833678.000-97%219658537284.643-97%
Net Profit Margin--0.1170.1170%0.121-4%0.117+0%0.1170%
Operating Margin--0.1450.1450%0.152-4%0.149-3%0.153-6%
Operating Ratio--0.8550.8550%0.848+1%0.957-11%1.162-26%
Pb Ratio3.438-22%4.1864.1860%3.454+21%2.447+71%1.232+240%
Pe Ratio214348.679-22%260986.064260986.0640%16.232+1607722%53011.432+392%27001.824+867%
Price Per Share21.050-22%25.63025.6300%22.050+16%18.418+39%20.874+23%
Price To Free Cash Flow Ratio1747656.731-22%2127906.9842127906.9840%394605.641+439%766939.798+177%384980.961+453%
Price To Total Gains Ratio-80.197+18%-97.646-97.6460%26.927-463%-17.521-82%-7.786-92%
Quick Ratio--2.0372.0370%2.908-30%2.431-16%1.797+13%
Return On Assets--0.0000.0000%0.000+6%0.000+4%0.000-7%
Return On Equity--0.0000.0000%0.000+8%0.000+8%0.000-5%
Total Gains Per Share---0.262-0.2620%0.819-132%-58.056+22018%0.766-134%
Usd Book Value--1423888380.0001423888380.0000%1496343620.000-5%3060004567359.000-100%7086024672983.600-100%
Usd Book Value Change Per Share---0.263-0.2630%0.819-132%-58.057+22015%0.612-143%
Usd Book Value Per Share--6.1226.1220%6.385-4%69.898-91%18080.221-100%
Usd Dividend Per Share--0.0000.0000%0.000+21%0.001-91%0.154-100%
Usd Eps--0.0000.0000%1.358-100%0.720-100%0.719-100%
Usd Free Cash Flow--2801.3532801.3530%13095.967-79%27963215.399-100%21709945.792-100%
Usd Free Cash Flow Per Share--0.0000.0000%0.000-78%0.001-98%0.001-98%
Usd Free Cash Flow To Equity Per Share--0.0000.0000%0.000-98%0.000-152%0.000-400%
Usd Market Cap4868401900.000-22%5961017762.2605961017762.2600%5167742406.750+15%201513833678.000-97%219658537284.643-97%
Usd Price Per Share21.050-22%25.63025.6300%22.050+16%18.418+39%20.874+23%
Usd Profit--22840.36822840.3680%22239.250+3%49158879.667-100%131510513.997-100%
Usd Revenue--195390.557195390.5570%183448.095+7%421625506.028-100%1118957542.534-100%
Usd Total Gains Per Share---0.262-0.2620%0.819-132%-58.056+22018%0.766-134%
 EOD+5 -3MRQTTM+0 -0YOY+9 -275Y+9 -2710Y+4 -32

3.2. Fundamental Score

Let's check the fundamental score of Kalbe Farma Tbk PT ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15214,348.679
Price to Book Ratio (EOD)Between0-13.438
Net Profit Margin (MRQ)Greater than00.117
Operating Margin (MRQ)Greater than00.145
Quick Ratio (MRQ)Greater than12.037
Current Ratio (MRQ)Greater than13.771
Debt to Asset Ratio (MRQ)Less than10.189
Debt to Equity Ratio (MRQ)Less than10.252
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.000
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Kalbe Farma Tbk PT ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose21.050
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,755,352
Total Liabilities331,464
Total Stockholder Equity1,313,565
 As reported
Total Liabilities 331,464
Total Stockholder Equity+ 1,313,565
Total Assets = 1,755,352

Assets

Total Assets1,755,352
Total Current Assets1,076,759
Long-term Assets678,593
Total Current Assets
Cash And Cash Equivalents 254,512
Short-term Investments 9,363
Net Receivables 308,510
Inventory 460,005
Other Current Assets 44,369
Total Current Assets  (as reported)1,076,759
Total Current Assets  (calculated)1,076,759
+/- 0
Long-term Assets
Property Plant Equipment 535,799
Goodwill 30,888
Intangible Assets 1,066,868,756
Long-term Assets Other -1,546,106,376
Long-term Assets  (as reported)678,593
Long-term Assets  (calculated)-478,670,933
+/- 479,349,526

Liabilities & Shareholders' Equity

Total Current Liabilities285,523
Long-term Liabilities45,940
Total Stockholder Equity1,313,565
Total Current Liabilities
Short-term Debt 55,147
Short Long Term Debt 829,302,294
Accounts payable 128,656
Other Current Liabilities 87,918
Total Current Liabilities  (as reported)285,523
Total Current Liabilities  (calculated)829,574,015
+/- 829,288,491
Long-term Liabilities
Long-term Liabilities  (as reported)45,940
Long-term Liabilities  (calculated)0
+/- 45,940
Total Stockholder Equity
Common Stock30,205
Retained Earnings 1,300,827
Accumulated Other Comprehensive Income 49,424
Other Stockholders Equity -66,892
Total Stockholder Equity (as reported)1,313,565
Total Stockholder Equity (calculated)1,313,565
+/-0
Other
Capital Stock468,751,221
Cash and Short Term Investments 263,875
Common Stock Shares Outstanding 232,580
Current Deferred Revenue13,803
Liabilities and Stockholders Equity 1,755,352
Net Debt -179,267
Net Invested Capital 21,501,551,097
Net Working Capital 12,279,191,111
Property Plant and Equipment Gross 13,554,403,439
Short Long Term Debt Total 75,244



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-311996-12-311995-12-311994-12-31
> Total Assets 
0
0
0
11,315,061,275
12,439,267,396
13,696,417,381
15,226,009,211
16,616,239,416
18,146,206,145
1,459,732
1,610,524
1,805,997
1,755,352
1,755,3521,805,9971,610,5241,459,73218,146,206,14516,616,239,41615,226,009,21113,696,417,38112,439,267,39611,315,061,275000
   > Total Current Assets 
642,498,522
777,803,875
788,624,853
7,497,319,452
8,120,805,370
8,745,465,559
9,572,529,768
10,042,738,650
10,648,288,387
808,391
933,250
1,105,568
1,076,759
1,076,7591,105,568933,250808,39110,648,288,38710,042,738,6509,572,529,7688,745,465,5598,120,805,3707,497,319,452788,624,853777,803,875642,498,522
       Cash And Cash Equivalents 
0
0
0
1,426,460,967
1,894,609,528
2,718,619,233
2,895,582,003
2,784,705,831
3,153,327,557
219,016
371,715
437,398
254,512
254,512437,398371,715219,0163,153,327,5572,784,705,8312,895,582,0032,718,619,2331,894,609,5281,426,460,967000
       Short-term Investments 
0
0
0
187,742,938
199,389,673
155,753,503
179,326,121
186,495,243
178,719,216
14,091
13,441
18,219
9,363
9,36318,21913,44114,091178,719,216186,495,243179,326,121155,753,503199,389,673187,742,938000
       Net Receivables 
124,924,176
202,543,236
204,814,580
2,273,378,788
2,464,901,530
2,434,081,759
2,725,807,581
2,967,693,268
3,373,569,270
266,354
256,587
249,449
308,510
308,510249,449256,587266,3543,373,569,2702,967,693,2682,725,807,5812,434,081,7592,464,901,5302,273,378,788204,814,580202,543,236124,924,176
       Inventory 
85,300,596
98,854,311
78,360,387
3,053,494,514
3,090,544,151
3,003,149,536
3,344,404,151
3,557,496,638
3,602,941,730
279,856
267,304
363,258
460,005
460,005363,258267,304279,8563,602,941,7303,557,496,6383,344,404,1513,003,149,5363,090,544,1513,053,494,51478,360,38798,854,31185,300,596
   > Long-term Assets 
0
0
0
0
0
0
5,653,479,443
6,572,288,916
7,497,917,759
651,341
677,274
700,429
678,593
678,593700,429677,274651,3417,497,917,7596,572,288,9165,653,479,443000000
       Property Plant Equipment 
135,843,984
151,023,963
175,029,461
2,925,546,783
3,404,457,131
3,938,494,051
4,555,756,102
5,342,659,713
6,252,801,150
575,826
607,208
586,327
535,799
535,799586,327607,208575,8266,252,801,1505,342,659,7134,555,756,1023,938,494,0513,404,457,1312,925,546,783175,029,461151,023,963135,843,984
       Goodwill 
0
0
0
294,015,103
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
21,126
13,934
14,754
30,888
30,88814,75413,93421,126293,279,778293,279,778293,279,778293,279,778293,279,778294,015,103000
       Long Term Investments 
0
0
0
42,420,010
40,833,502
57,650,343
89,131,940
78,861,566
86,106,431
0
0
0
0
000086,106,43178,861,56689,131,94057,650,34340,833,50242,420,010000
       Intangible Assets 
0
0
0
91,252,475
128,428,194
121,999,977
106,926,537
126,293,051
171,022,168
420,475,565
523,720,406
961,154,387
1,066,868,756
1,066,868,756961,154,387523,720,406420,475,565171,022,168126,293,051106,926,537121,999,977128,428,19491,252,475000
       Long-term Assets Other 
0
0
0
0
0
0
41,987,336
23,186,238
28,066,107
-713,696,268
-718,891,095
-1,170,751,615
-1,546,106,376
-1,546,106,376-1,170,751,615-718,891,095-713,696,26828,066,10723,186,23841,987,336000000
> Total Liabilities 
0
0
0
2,815,103,309
2,675,166,378
2,758,131,396
2,762,162,070
2,722,207,634
2,851,611,349
256,376
306,071
309,653
331,464
331,464309,653306,071256,3762,851,611,3492,722,207,6342,762,162,0702,758,131,3962,675,166,3782,815,103,309000
   > Total Current Liabilities 
293,146,778
253,736,914
193,867,231
2,640,590,024
2,385,920,172
2,365,880,491
2,317,161,787
2,227,336,012
2,286,167,472
185,637
226,738
248,711
285,523
285,523248,711226,738185,6372,286,167,4722,227,336,0122,317,161,7872,365,880,4912,385,920,1722,640,590,024193,867,231253,736,914293,146,778
       Short-term Debt 
0
0
0
583,915,300
296,128,806
0
0
0
0
12,185
26,356
6,589
55,147
55,1476,58926,35612,1850000296,128,806583,915,300000
       Short Long Term Debt 
0
0
0
583,915,300
296,128,806
8,489,086
147,394,441
171,441,295
96,257,226
169,062,533
344,343,143
69,999,978
829,302,294
829,302,29469,999,978344,343,143169,062,53396,257,226171,441,295147,394,4418,489,086296,128,806583,915,300000
       Accounts payable 
31,304,142
23,331,297
21,145,970
1,151,654,580
1,133,092,820
1,068,665,524
1,127,307,240
1,108,551,385
1,289,897,769
87,582
88,532
117,338
128,656
128,656117,33888,53287,5821,289,897,7691,108,551,3851,127,307,2401,068,665,5241,133,092,8201,151,654,58021,145,97023,331,29731,304,142
       Other Current Liabilities 
29,373,535
17,548,365
32,410,687
497,589,641
560,131,137
529,770,463
601,568,161
599,028,509
560,236,764
76,497
88,903
105,744
87,918
87,918105,74488,90376,497560,236,764599,028,509601,568,161529,770,463560,131,137497,589,64132,410,68717,548,36529,373,535
   > Long-term Liabilities 
0
0
0
0
0
0
445,000,282
494,871,622
565,443,877
70,739
79,333
60,942
45,940
45,94060,94279,33370,739565,443,877494,871,622445,000,282000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
-583,915,300
-296,128,806
0
3,474,185
3,212,114
1,319,212
123,197
90,627,221
65,871,410
51,329,420
51,329,42065,871,41090,627,221123,1971,319,2123,212,1143,474,1850-296,128,806-583,915,300000
       Other Liabilities 
2,158,373
1,445,930
0
174,513,286
245,026,501
261,317,981
310,583,306
349,268,627
305,442,034
334,347,236
323,440,239
333,591,797
0
0333,591,797323,440,239334,347,236305,442,034349,268,627310,583,306261,317,981245,026,501174,513,28601,445,9302,158,373
> Total Stockholder Equity
0
0
0
8,108,241,522
9,330,078,909
10,465,122,964
11,909,264,708
13,280,807,475
14,623,457,976
1,144,832
1,242,318
1,377,686
1,313,565
1,313,5651,377,6861,242,3181,144,83214,623,457,97613,280,807,47511,909,264,70810,465,122,9649,330,078,9098,108,241,522000
   Retained Earnings 
95,280,838
142,186,854
190,454,329
7,633,188,371
8,892,787,975
10,006,397,635
11,415,504,887
12,787,858,134
14,073,109,114
1,090,233
1,186,582
1,299,509
1,300,827
1,300,8271,299,5091,186,5821,090,23314,073,109,11412,787,858,13411,415,504,88710,006,397,6358,892,787,9757,633,188,371190,454,329142,186,85495,280,838
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
23,291
24,861
47,740
49,424
49,42447,74024,86123,291000000000
   Capital Surplus 0000000000000
   Treasury Stock0000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in IDR. All numbers in thousands.




Income Statement

Currency in IDR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue30,312,738,428
Cost of Revenue-18,436,428,298
Gross Profit11,876,310,13011,876,310,130
 
Operating Income (+$)
Gross Profit11,876,310,130
Operating Expense-26,520,567,707
Operating Income3,792,170,722-14,644,257,576
 
Operating Expense (+$)
Research Development585,303,493
Selling General Administrative4,232,069,094
Selling And Marketing Expenses-
Operating Expense26,520,567,7074,817,372,587
 
Net Interest Income (+$)
Interest Income79,901,033
Interest Expense-82,117,347
Other Finance Cost-14,414,684
Net Interest Income-16,630,998
 
Pretax Income (+$)
Operating Income3,792,170,722
Net Interest Income-16,630,998
Other Non-Operating Income Expenses-
Income Before Tax (EBT)3,873,532,3833,792,170,722
EBIT - interestExpense = -82,117,347
2,961,621,388
3,043,738,735
Interest Expense82,117,347
Earnings Before Interest and Taxes (EBIT)-3,955,649,729
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax3,873,532,383
Tax Provision-884,367,959
Net Income From Continuing Ops2,989,164,4242,989,164,424
Net Income2,961,621,388
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-16,630,998
 

Technical Analysis of Kalbe
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kalbe. The general trend of Kalbe is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kalbe's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kalbe Farma Tbk PT ADR.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 21.05 < 21.05 < 21.05.

The bearish price targets are: 21.05 > 21.05 > 21.05.

Tweet this
Kalbe Farma Tbk PT ADR Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kalbe Farma Tbk PT ADR. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kalbe Farma Tbk PT ADR Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Moving Average Convergence/Divergence (MACD) ChartKalbe Farma Tbk PT ADR Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kalbe Farma Tbk PT ADR. The current adx is .

Kalbe Farma Tbk PT ADR Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Relative Strength Index (RSI) ChartKalbe Farma Tbk PT ADR Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Stochastic Oscillator ChartKalbe Farma Tbk PT ADR Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Commodity Channel Index (CCI) ChartKalbe Farma Tbk PT ADR Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Chande Momentum Oscillator (CMO) ChartKalbe Farma Tbk PT ADR Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Williams %R ChartKalbe Farma Tbk PT ADR Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Average True Range (ATR) ChartKalbe Farma Tbk PT ADR Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily On-Balance Volume (OBV) ChartKalbe Farma Tbk PT ADR Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kalbe Farma Tbk PT ADR.

Kalbe Farma Tbk PT ADR Daily Money Flow Index (MFI) ChartKalbe Farma Tbk PT ADR Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kalbe Farma Tbk PT ADR.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Kalbe Farma Tbk PT ADR Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kalbe Farma Tbk PT ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose21.050
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kalbe with someone you think should read this too:
  • Are you bullish or bearish on Kalbe? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kalbe? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kalbe Farma Tbk PT ADR

I send you an email if I find something interesting about Kalbe Farma Tbk PT ADR.


Comments

How you think about this?

Leave a comment

Stay informed about Kalbe Farma Tbk PT ADR.

Receive notifications about Kalbe Farma Tbk PT ADR in your mailbox!